We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Microarray-Based Glycoprofiling Test Diagnoses Ovarian Cancer

By LabMedica International staff writers
Posted on 27 Mar 2014
Cancer researchers have developed a microarray assay that identifies the abnormally glycosylated surface residues associated with ovarian tumor biomarker proteins such as CA125.

The CA125 biomarker assay plays an important role in the diagnosis and management of invasive ovarian cancer. More...
However, a fundamental problem with CA125 is that it is not cancer-specific and may be elevated in benign gynecological conditions such as benign ovarian neoplasms and endometriosis.

Investigators at the University of Copenhagen (Denmark) based the development of a new assay system for glycoprofiling ovarian cancer on the observation that aberrant O-glycosylation was an inherent and specific property of cancer cells and could aid in differentiating cancer from these benign conditions, thereby improving specificity of the assay.

They developed a novel microarray-based platform for profiling specific aberrant glycoforms, such as Neu5Acalpha2,6GalNAc (STn) and GalNAc (Tn), present on CA125 and CA15-3. They used the assay to measure STn-CA125, ST-CA125, and STn-CA15-3 in a blinded study of a cohort of patients from the United Kingdom Ovarian Cancer Population Study who presented with elevated CA125 levels and a pelvic mass.

Results revealed that the combined glycoform profile was able to distinguish benign ovarian neoplasms from invasive epithelial ovarian cancer with a specificity of 61.1% at 90% sensitivity.

“All proteins have a type of sugar-coat – small, complicated sugar molecules that reside on a protein’s surface. When cancer is present in the body, we can observe a chemical change in this sugar-coat. It is a very complex phenomenon. Luckily, it is very simple to investigate and determine the presence of this transformed sugar coating,” said senior author Dr. Ola Blixt, professor of chemistry at the University of Copenhagen. “We have decided to publish these results, as opposed to taking out a patent. OK, we will not get rich, even though the market related to ovarian cancer is worth 170 million USD annually. On the other hand, any manufacturer is able to include this in their existing kit. And I hope that it happens soon.”

The study describing the ovarian cancer glycoprofiling assay was published in the January 29, 2014, online edition of the Journal of Proteome Research.

Related Links:

University of Copenhagen



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.